

Cipla

Cipla Ltd.

Registered Office :
Cipla House
Peninsula Business Park
Ganpatrao Kadam Marg
Lower Parel
Mumbai – 400 013
India

23rd December 2014

(1) BSE Ltd
Listing Department,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai 400 001

(2) National Stock Exchange of India Ltd
Listing Department
Exchange Plaza, 5th floor,
Plot no. C/1, G Block,
Bandra Kurla Complex,
Bandra (East), Mumbai - 400 051

Scrip Code: 500087

Scrip Code: CIPLA EQ

(3) SOCIETE DE LA BOURSE DE LUXEMBERG
Societe Anonyme
11, av de la Porte-Neuve,
L-2227 Luxemburg

Dear Sirs,

We are forwarding herewith copy of press release dated 23rd December 2014 issued by Company's South African subsidiary titled "CIPLA MEDPRO WINS R2 BILLION OF STATE ARV TENDER". Kindly note that this development is in the ordinary course of business and is being sent to stock exchanges out of abundant caution.

Kindly acknowledge the receipt.

Thank you,

Yours faithfully,
For Cipla Limited



Mital Sanghvi
Company Secretary

Encl.: as above



PRESS RELEASE

CIPLA MEDPRO WINS R2 BILLION OF STATE ARV TENDER

December 23rd, 2014: Cipla Medpro, the third largest pharmaceutical company in South Africa, today announced that it has been awarded R2 billion share of the South African Government's 2015-17 National ARV tender. The contract is effective from the 1st of April 2015 and will run for a period of three years.

CEO of Cipla Medpro, Paul Miller, says that Cipla is proud to have been recognised once again as a preferred partner of the State in the national fight against HIV and Aids. "Cipla is known as a pioneer of fixed dose combinations following Cipla's Dr Yusuf Hamied's accomplishment of making Aids medication available for a dollar a day in 2001." Cipla also went further and made this triple combination available in the world's first 3-in-1 combination ARV.

"We intend to continue this proud tradition and build on the foundation laid to continue our quest of providing affordable healthcare to all," Miller adds.

This latest Government tender win is the third in the last year for the growing pharmaceutical company, and follows Cipla Medpro winning a R280 million state therapeutic drug tender (August 2014), a R345 million national respiratory tender (June 2014).

The medication will be produced at its state-of-the-art, 23 000 square meter manufacturing site, Cipla Medpro Manufacturing (CMM), which is based in Kwazulu-Natal. "CMM employs approximately 300 staff members, 98% of which are previously disadvantaged".

The organisation is currently developing unique fixed dose combinations (FDCs) and formulations and will continue to promote new molecules and innovative fixed-dose combinations as well as licencing agreements to ensure fair returns for investors and affordable prices for patients.

"We are extremely proud to have won this tender which is not only testament to our high quality product portfolio, but is also in line with Cipla's ethos of advancing healthcare for all South Africans. We look forward to continuing this partnership with government - united in the fight against Aids," concludes Subhanu Saxena, MD & Global CEO of Cipla Limited.

-Ends-

About Cipla Medpro:

Cipla Medpro - the third largest pharmaceutical company in South Africa - is a leading provider of affordable medicines to the public and private sectors. Cipla Medpro manufactures world class pharmaceuticals at cost-effective prices, making quality medicines affordable, and advancing healthcare for all South Africans.



About Cipla Limited:

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients. For more than 70 years, Cipla has emerged as one of the most respected pharmaceutical names in India as well as across more than 150 countries. Our portfolio includes over 1500 products across wide range of therapeutic categories with one quality standard globally. Cipla's turnover in FY 2013-14 was 1.7 billion USD.

Whilst delivering a long-term sustainable business, Cipla recognises its duty to provide affordable medicines. Cipla's emphasis on access for patients was recognized globally for the pioneering role played in HIV/AIDS treatment as the first pharmaceutical company to provide a triple combination anti-retroviral (ARV) in Africa at less than one dollar a day and thereby treating many millions of patients since 2001.

Cipla's research and development focuses on developing innovative products and drug delivery systems and has given India and the world many 'firsts' for instance Triomune. In a tightly regulated environment, the company's manufacturing facilities have approvals from all the main regulators including US FDA, UKMHRA, WHO, MCC, ANVISA, and PMDA which means the company provides one universal standard both domestically and internationally.